119 related articles for article (PubMed ID: 33668642)
1. The BET Inhibitor OTX015 Exhibits In Vitro and In Vivo Antitumor Activity in Pediatric Ependymoma Stem Cell Models.
Servidei T; Meco D; Martini M; Battaglia A; Granitto A; Buzzonetti A; Babini G; Massimi L; Tamburrini G; Scambia G; Ruggiero A; Riccardi R
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33668642
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologic Targeting of Histone H3K27 Acetylation/BRD4-dependent Induction of ALDH1A3 for Early-phase Drug Tolerance of Gastric Cancer.
Lee J; Mashima T; Kawata N; Yamamoto N; Morino S; Inaba S; Nakamura A; Kumagai K; Wakatsuki T; Takeuchi K; Yamaguchi K; Seimiya H
Cancer Res Commun; 2024 May; 4(5):1307-1320. PubMed ID: 38669046
[TBL] [Abstract][Full Text] [Related]
3. Targeting bromodomain and extraterminal proteins in breast cancer.
Sahni JM; Keri RA
Pharmacol Res; 2018 Mar; 129():156-176. PubMed ID: 29154989
[TBL] [Abstract][Full Text] [Related]
4. Dual inhibition of BET and HAT/p300 suppresses colorectal cancer via DR5- and p53/PUMA-mediated cell death.
Kuang C; Tong J; Ermine K; Cai M; Dai F; Hao S; Giles F; Huang Y; Yu J; Zhang L
Front Oncol; 2022; 12():1018775. PubMed ID: 36313707
[TBL] [Abstract][Full Text] [Related]
5. MYC family amplification dictates sensitivity to BET bromodomain protein inhibitor Mivebresib (ABBV-075) in small-cell lung cancer.
Plotnik JP; Zha Z; Feng W; Lee I; Riehm J; McClure RA; Sandoval S; Uziel T; Murphy E; Lu X; Lam LT
Mol Cancer Res; 2024 May; ():. PubMed ID: 38747975
[TBL] [Abstract][Full Text] [Related]
6. Systematic, network-based characterization of therapeutic target inhibitors.
Shen Y; Alvarez MJ; Bisikirska B; Lachmann A; Realubit R; Pampou S; Coku J; Karan C; Califano A
PLoS Comput Biol; 2017 Oct; 13(10):e1005599. PubMed ID: 29023443
[TBL] [Abstract][Full Text] [Related]
7. Targeting of vulnerabilities of drug-tolerant persisters identified through functional genetics delays tumor relapse.
Chen M; Mainardi S; Lieftink C; Velds A; de Rink I; Yang C; Kuiken HJ; Morris B; Edwards F; Jochems F; van Tellingen O; Boeije M; Proost N; Jansen RA; Qin S; Jin H; Koen van der Mijn JC; Schepers A; Venkatesan S; Qin W; Beijersbergen RL; Wang L; Bernards R
Cell Rep Med; 2024 Mar; 5(3):101471. PubMed ID: 38508142
[TBL] [Abstract][Full Text] [Related]
8. ZFTA-RELA Dictates Oncogenic Transcriptional Programs to Drive Aggressive Supratentorial Ependymoma.
Arabzade A; Zhao Y; Varadharajan S; Chen HC; Jessa S; Rivas B; Stuckert AJ; Solis M; Kardian A; Tlais D; Golbourn BJ; Stanton AJ; Chan YS; Olson C; Karlin KL; Kong K; Kupp R; Hu B; Injac SG; Ngo M; Wang PR; De León LA; Sahm F; Kawauchi D; Pfister SM; Lin CY; Hodges HC; Singh I; Westbrook TF; Chintagumpala MM; Blaney SM; Parsons DW; Pajtler KW; Agnihotri S; Gilbertson RJ; Yi J; Jabado N; Kleinman CL; Bertrand KC; Deneen B; Mack SC
Cancer Discov; 2021 Sep; 11(9):2200-2215. PubMed ID: 33741710
[TBL] [Abstract][Full Text] [Related]
9.
Kupp R; Ruff L; Terranova S; Nathan E; Ballereau S; Stark R; Sekhar Reddy Chilamakuri C; Hoffmann N; Wickham-Rahrmann K; Widdess M; Arabzade A; Zhao Y; Varadharajan S; Zheng T; Murugesan M; Pfister SM; Kawauchi D; Pajtler KW; Deneen B; Mack SC; Masih KE; Gryder BE; Khan J; Gilbertson RJ
Cancer Discov; 2021 Sep; 11(9):2216-2229. PubMed ID: 33741711
[No Abstract] [Full Text] [Related]
10. Cross-Species Genomics Reveals Oncogenic Dependencies in ZFTA/C11orf95 Fusion-Positive Supratentorial Ependymomas.
Zheng T; Ghasemi DR; Okonechnikov K; Korshunov A; Sill M; Maass KK; Benites Goncalves da Silva P; Ryzhova M; Gojo J; Stichel D; Arabzade A; Kupp R; Benzel J; Taya S; Adachi T; Shiraishi R; Gerber NU; Sturm D; Ecker J; Sievers P; Selt F; Chapman R; Haberler C; Figarella-Branger D; Reifenberger G; Fleischhack G; Rutkowski S; Donson AM; Ramaswamy V; Capper D; Ellison DW; Herold-Mende CC; Schüller U; Brandner S; Driever PH; Kros JM; Snuderl M; Milde T; Grundy RG; Hoshino M; Mack SC; Gilbertson RJ; Jones DTW; Kool M; von Deimling A; Pfister SM; Sahm F; Kawauchi D; Pajtler KW
Cancer Discov; 2021 Sep; 11(9):2230-2247. PubMed ID: 33879448
[TBL] [Abstract][Full Text] [Related]
11. BLBP Is Both a Marker for Poor Prognosis and a Potential Therapeutic Target in Paediatric Ependymoma.
Sabnis DH; Liu JF; Simmonds L; Blackburn S; Grundy RG; Kerr ID; Coyle B
Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33925302
[TBL] [Abstract][Full Text] [Related]
12. Identification of key methylation differentially expressed genes in posterior fossa ependymoma based on epigenomic and transcriptome analysis.
Wang G; Jia Y; Ye Y; Kang E; Chen H; Wang J; He X
J Transl Med; 2021 Apr; 19(1):174. PubMed ID: 33902636
[TBL] [Abstract][Full Text] [Related]
13. TERT promoter mutation and chromosome 6 loss define a high-risk subtype of ependymoma evolving from posterior fossa subependymoma.
Thomas C; Thierfelder F; Träger M; Soschinski P; Müther M; Edelmann D; Förster A; Geiler C; Kim HY; Filipski K; Harter PN; Schittenhelm J; Eckert F; Ntoulias G; May SA; Stummer W; Onken J; Vajkoczy P; Schüller U; Heppner FL; Capper D; Koch A; Kaul D; Paulus W; Hasselblatt M; Schweizer L
Acta Neuropathol; 2021 Jun; 141(6):959-970. PubMed ID: 33755803
[TBL] [Abstract][Full Text] [Related]
14. An epithelial-mesenchymal transition-related 5-gene signature predicting the prognosis of hepatocellular carcinoma patients.
Zhu G; Xia H; Tang Q; Bi F
Cancer Cell Int; 2021 Mar; 21(1):166. PubMed ID: 33712026
[TBL] [Abstract][Full Text] [Related]
15. Targeting fibroblast growth factor receptors to combat aggressive ependymoma.
Lötsch D; Kirchhofer D; Englinger B; Jiang L; Okonechnikov K; Senfter D; Laemmerer A; Gabler L; Pirker C; Donson AM; Bannauer P; Korbel P; Jaunecker CN; Hübner JM; Mayr L; Madlener S; Schmook MT; Ricken G; Maaß K; Grusch M; Holzmann K; Grasl-Kraupp B; Spiegl-Kreinecker S; Hsu J; Dorfer C; Rössler K; Azizi AA; Foreman NK; Peyrl A; Haberler C; Czech T; Slavc I; Filbin MG; Pajtler KW; Kool M; Berger W; Gojo J
Acta Neuropathol; 2021 Aug; 142(2):339-360. PubMed ID: 34046693
[TBL] [Abstract][Full Text] [Related]
16. RFX2 promotes tumor cell stemness through epigenetic regulation of PAF1 in spinal ependymoma.
Zhang Z; Chen Y; Guo Y; Shen H; Wang J; Chen H
J Neurooncol; 2023 Dec; 165(3):487-497. PubMed ID: 38057505
[TBL] [Abstract][Full Text] [Related]
17. KSHV vIL-6 enhances inflammatory responses by epigenetic reprogramming.
Inagaki T; Wang KH; Kumar A; Izumiya C; Miura H; Komaki S; Davis RR; Tepper CG; Katano H; Shimoda M; Izumiya Y
PLoS Pathog; 2023 Nov; 19(11):e1011771. PubMed ID: 37934757
[TBL] [Abstract][Full Text] [Related]
18. Targeting H3K27me3 loss in pediatric brain tumors - a perspective on epigenetically guided cancer therapy.
Goldstein M
Oncotarget; 2023 May; 14():444-447. PubMed ID: 37171381
[No Abstract] [Full Text] [Related]
19. Targeted Epigenetic Interventions in Cancer with an Emphasis on Pediatric Malignancies.
Gaál Z
Biomolecules; 2022 Dec; 13(1):. PubMed ID: 36671446
[TBL] [Abstract][Full Text] [Related]
20. Special Issue "Tumors of the Nervous System: New Insights into Signaling, Genetics and Therapeutic Targeting".
Di Bartolomeo S; Segatto M
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
